Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020251916 - REAGENTS AND METHODS FOR CANCER DETECTION, PROGNOSIS, AND THERAPEUTIC MONITORING

Publication Number WO/2020/251916
Publication Date 17.12.2020
International Application No. PCT/US2020/036744
International Filing Date 09.06.2020
IPC
G01N 33/574 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
CPC
G01N 2333/8125
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
81Protease inhibitors
8107Endopeptidase (E.C. 3.4.21-99) inhibitors
811Serine protease (E.C. 3.4.21) inhibitors
8121Serpins
8125Alpha-1-antitrypsin
G01N 33/574
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
G01N 33/57415
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
574for cancer
57407Specifically defined cancers
57415of breast
Applicants
  • SANFORD HEALTH [US]/[US]
  • INANOVATE, INC. [US]/[US]
Inventors
  • EGLAND, Kristi
  • EVANS, Rick
  • THIRUPPATHI, Eagappanath
  • URE, David
  • KOSTURA, Matt
  • GNIMPIEBA, Etienne
Agents
  • HARPER, David, S.
Priority Data
62/859,26410.06.2019US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) REAGENTS AND METHODS FOR CANCER DETECTION, PROGNOSIS, AND THERAPEUTIC MONITORING
(FR) RÉACTIFS ET MÉTHODES DE DÉTECTION, DE PRONOSTIC ET DE SURVEILLANCE THÉRAPEUTIQUE DU CANCER
Abstract
(EN) Methods and related reagents are disclosed for diagnosing cancer, prognosing cancer occurrence or recurrence, and/or monitoring cancer therapy, involving contacting a bodily fluid sample from a subject at risk of having cancer or cancer recurrence, or from a subject that has been treated for cancer wl fit (a)one or more first antibody detection marker molecules that hind to human autoantibodies against at least one tumor associated antigen (TAA); and (fa) one or more second antibody detection marker molecules that bind to human autoantibodies against at least one extractable nuclear antigen (ENA).
(FR) L'invention concerne des méthodes et des réactifs associés destinés au diagnostic du cancer, au pronostic de l'apparition ou de la récidive du cancer, et/ou à la surveillance d'une thérapie anticancéreuse, impliquant la mise en contact d'un échantillon de fluide corporel prélevé auprès d'un sujet présentant un risque de cancer ou d'une récidive du cancer, ou d'un sujet qui a été traité contre le cancer (a) à l'aide d'une ou de plusieurs premières molécules de marqueur de détection d'anticorps qui se lient à des auto-anticorps humains dirigés contre au moins un antigène associé à une tumeur (TAA); et (fa) à l'aide d'une ou de plusieurs secondes molécules de marqueur de détection d'anticorps qui se lient à des auto-anticorps humains contre au moins un antigène nucléaire extractible (ENA).
Related patent documents
EP2020751332This application is not viewable in PATENTSCOPE because the national phase entry has not been published yet or the national entry is issued from a country that does not share data with WIPO or there is a formatting issue or an unavailability of the application.
Latest bibliographic data on file with the International Bureau